---
document_datetime: 2024-03-27 11:31:23
document_pages: 21
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/arixtra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: arixtra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 13.8206888
conversion_datetime: 2025-12-23 05:54:44.497014
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Arixtra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0091               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 21/03/2024                          |                                             | PL                               |           |
| T/0090               | Transfer of Marketing Authorisation                                                              | 18/01/2024                          | 16/02/2024                                  | SmPC, Labelling and              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            | PL              |                       |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------|
| IA/0089     | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                      | 30/10/2023 | n/a        |                 |                       |
| II/0087     | To update section 4.8 of the SmPC to update the ADR table following the assessment of PSUSA (EMEA/H/C/PSUSA/00001467/202112). The Package Leaflet is updated accordingly. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the A 45/46 - Other variation                                                                                                                                              | 28/09/2023 | 16/02/2024 | SmPC and PL     | assessment done under |
| IAIN/0088/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 13/07/2023 | 16/02/2024 | Annex II and PL |                       |
| N/0086      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                | 28/10/2022 | 16/02/2024 | PL              |                       |

<div style=\"page-break-after: always\"></div>

| PSUSA/1467/ 202112   | Periodic Safety Update EU Single assessment - fondaparinux                                                                                                                                                                                                                                                                                                                                                                                            | 07/07/2022   | n/a        |                        | PRAC Recommendation - maintenance   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| N/0084               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                      | 03/11/2021   | 16/02/2024 | PL                     |                                     |
| N/0083               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                      | 07/09/2021   | 16/02/2024 | PL                     |                                     |
| T/0082               | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/02/2021   | 17/03/2021 | SmPC, Labelling and PL |                                     |
| N/0081               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                      | 17/12/2020   | 17/03/2021 | PL                     |                                     |
| IA/0080              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                         | 15/05/2020   | n/a        |                        |                                     |
| IB/0079/G            | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size | 19/09/2019   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

|                    | and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS   |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/1467/ 201812 | Periodic Safety Update EU Single assessment - fondaparinux                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/06/2019 | n/a | PRAC Recommendation - maintenance |
| IB/0078            | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 05/04/2019 | n/a |                                   |
| IA/0076/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                | 22/11/2018 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method   |            |            |             |                                                                                                                                           |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| N/0075             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/11/2018 | 17/03/2021 | PL          |                                                                                                                                           |
| PSUSA/1467/ 201712 | Periodic Safety Update EU Single assessment - fondaparinux                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 28/06/2018 | 23/08/2018 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1467/201712. |
| IA/0074/G          | This was an application for a group of variations. B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                      | 13/07/2018 | n/a        |             |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                         |            |            |           |                                                                                                                                                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0072             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                   | 21/03/2018 | 23/08/2018 | Labelling |                                                                                                                                                                |
| PSUSA/1467/ 201612 | Periodic Safety Update EU Single assessment - fondaparinux                                                                                                                                                                                                                                                                                         | 06/07/2017 | n/a        |           | PRAC Recommendation - maintenance                                                                                                                              |
| PSUSA/1467/ 201512 | Periodic Safety Update EU Single assessment - fondaparinux                                                                                                                                                                                                                                                                                         | 21/07/2016 | 15/09/2016 | SmPC      | Please refer to Arixtra PSUSA-00001467-201512 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IB/0069/G          | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size | 25/02/2016 | n/a        |           |                                                                                                                                                                |
| IAIN/0068          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                    | 09/12/2015 | n/a        |           |                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| II/0067            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                              | 19/11/2015   | n/a        |                        |                                                                                               |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------------------------------|
| PSUSA/1467/ 201412 | Periodic Safety Update EU Single assessment - fondaparinux                                                                                                                                                                                                                                                                                                                                                                 | 11/06/2015   | n/a        |                        | PRAC Recommendation - maintenance                                                             |
| IA/0065            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                               | 06/10/2014   | n/a        |                        |                                                                                               |
| IAIN/0064/G        | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 06/10/2014   | 30/09/2015 | Annex II and PL        |                                                                                               |
| PSUV/0062          | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                     | 11/09/2014   | n/a        |                        | PRAC Recommendation - maintenance                                                             |
| T/0063             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                        | 25/07/2014   | 26/08/2014 | SmPC, Labelling and PL | Transfer of the Marketing Authorisation from Glaxo Group Ltd to Aspen Pharma Trading Limited. |
| II/0061            | Submission of a revised RMP version 1.9, which has been aligned with the new RMP format and which                                                                                                                                                                                                                                                                                                                          | 26/06/2014   | n/a        |                        | N/A                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | includes an amendment of the current timeline for completion of the Superficial Vein Thrombosis post- marketing observational study from December 2013 to December 2014. The requested variation proposed no amendments to the PI. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                      |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0060  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/06/2014 | 26/08/2014 | Labelling and PL      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| N/0059  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/11/2013 | 26/08/2014 | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0056 | Update of section 4.8 of the SmPC in order to add angioedema and anaphylactoid/anaphylactic reaction as new adverse reaction for all strengths. The Package Leaflet was proposed to be updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 9. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 25/04/2013 | 29/11/2013 | SmPC, Annex II and PL | During the time period covered by the last fondaparinux PSUR, two reports were identified that described possible anaphylactic reactions. Following this the MAH committed to conduct a comprehensive review of anaphylaxis to further investigate a causal association between anaphylaxis and the use of fondaparinux. Following the review conducted by the MAH and assessed by the CHMP section 4.8 of the SmPC was updated in order to add angioedema and anaphylactoid/anaphylactic reaction as new adverse reaction for all strengths. |

<div style=\"page-break-after: always\"></div>

| IG/0279   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18/04/2013   | 29/11/2013   | SmPC, Labelling and PL   |                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------|
| IG/0275   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 15/03/2013   | n/a          |                          |                        |
| IB/0055/G | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products A.7 - Administrative change - Deletion of manufacturing sites B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place | 19/12/2012   | n/a          |                          | B.II.b.3.a - Change in |

<div style=\"page-break-after: always\"></div>

|           | the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                          |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0054   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                 | 14/12/2012 | 29/11/2013 | SmPC, Annex II, Labelling and PL | To update section 4.8 - Undesirable effects of the EU SmPC for the higher doses (5mg, 7,5mg, and 10 mg solution for injection) only with the following adverse reactions; abdominal pain (rare), hepatic enzymes increased (uncommon) and pruritus (rare). The following adverse reactions; gastritis, constipation, diarrhoea, and bilirubinaemia (reported in post marketing experience) will also be added as a statement under the table in section 4.8 for the higher dose (5mg, 7,5mg, and 10 mg) SmPCs. The possible side effects section of the Package leaflet has been updated in line with the updates to section 4.8 of the |
| IB/0052   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                 | 13/04/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IG/0150/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 05/04/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0051   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15/12/2011   | 04/07/2012   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049   | Update the Summary of Product Characteristics under section 4.4 Special Warnings and Precautions for Use, with the addition of a Latex Warning. Consequently, the Package Leaflet has also been updated. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-                                                                                                                                                                                                                                                                                         | 22/09/2011   | 20/10/2011   | SmPC and PL              | Fondaparinux sodium is supplied as a sterile, preservative- free injectable solution for subcutaneous and intravenous use, in a single dose pre-filled syringe. The needle guard of the syringe contains natural rubber (i.e. latex). Therefore a warning on the potential allergic reactions that might be caused by the latex has been added to the SmPC and PL.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0048   | Update of section 5.1 of the SmPC of the 2.5mg strength with data and information from a post- approval safety study conducted as a commitment following approval of the Acute Coronary Syndrom (ACS) indications. Consequently, section 4.4 of the SmPC of the 2.5mg strength is updated to reflect information on the risk of guiding cathete thrombus. Additionally, the SmPC and PL reflect some typo corrections and terminology improvements. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 14/04/2011   | 18/05/2011   | SmPC and PL              | This Type II variation is to update the Summary of Product Characteristics (SmPC sections 4.2, 4.4 and 5.1) of the 2.5mg strength to include data from the study FUTURA and a warning on the risk of guiding cathete thrombus. FUTURA is a post-approval safety study to evaluate the safety of two dose regimens of unfractionated heparin (UFH) as adjunctive to fondaparinux during percutaneous coronary intervention (PCI) in non-ST segment elevation myocardial infarction (NSTEMI) patients being treated initially with fondaparinux. The study was conducted as a commitment following approval of the Acute Coronary Syndrome (ACS) indication. The study results showed a trend for lower incidences of minor bleedings and large haematomas at the injection sites for the low dose group. However, an opposite trend was observed for ischemic complications at day 30. The study had an appropriate design and seems to have |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |      | been well performed. It has provided results that are of clinical interest and a short description of the main results in the SmPC is judged to be justified.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0047 | Update of sections 4.2, 5.1 and 5.2 of the SmPC with data from a phase II pilot dose-finding and pharmacokinetic study of fondaparinux in paediatric patients with Deep Vein Thrombosis (DVT). This update affects only the SmPCs relevant to the DVT indication (i.e. strengths 5, 7.5 and 10 mg). C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 20/01/2011 | 28/02/2011 | SmPC | ART113100 was a phase II pilot dose-finding and pharmacokinetic study of fondaparinux in patients with Deep Vein Thrombosis (DVT), aged 1-18 years and with a body weight greater than 8.3 kg. Data from this study were used to create a PK model for the paediatric population to compare concentrations achieved in paediatric patients receiving 0.1mg/kg/day to concentrations known to be efficacious in adults. The PK modelling used data from study ART113100 and study BDR3780, a bioequivalence study in adult healthy subjects. The BDR3780 clinical study report was part of the original Marketing Authorisation Application for Arixtra. The limited data provided in paediatrics collectively suggest that the exposure in children with dosing 0.1 mg/kg is somewhat lower than that observed in adults and that there is a trend for increased exposure with increased age within the paediatric population. From the results of this small uncontrolled study no firm conclusions can be drawn on an optimal concentration range to target in children in the treatment of thrombosis in the deep venous system. However, the CHMP was of the opinion that it could be of value for the prescribers to know what concentrations could be expected with a dose that, when adjusted to body-weight, is similar to what is recommended for adults. Therefore the CHMP agreed on the update of the SmPC to include data on this study. As the data concerns children with deep venous thrombosis, this information is only included in the SmPCs relevant for |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |          | this indication, i.e. the 5, 7.5 and 10 mg strengths.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|---------------------------------------------------------|
| IG/0034/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 06/01/2011 | n/a | Annex II |                                                         |

<div style=\"page-break-after: always\"></div>

| II/0045   | Please refer to the Scientific discussion: Arixtra-H- 403-II-45. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                          | 22/07/2010   | 31/08/2010   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044   | Addition of an alternative active substance manufacturer. Quality changes                                                                                                                                                                                | 20/05/2010   | 01/06/2010   |                          |                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0046   | To wash the wet Step 3 process intermediate DEFGH3 with aqueous acetonitrile in addition to or as an alternative to washing by water alone. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF  | 22/03/2010   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0043   | Update of the Detailed Description of the Pharmacovigilance System (DDPS) including change of the Qualified Person for Pharmacovigilance (QPPV). Consequently, Annex II has been updated with the new version number. Update of DDPS (Pharmacovigilance) | 17/12/2009   | 20/01/2010   | Annex II                 | The DDPS has been updated (version 7.2) to reflect the change of the QPPV as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils the requirements. |
| II/0042   | Changes to the specifications (appearance) and test methods of some starting materials, intermediates and reagents used in the synthesis of the active                                                                                                   | 24/09/2009   | 05/10/2009   |                          |                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | substance. Quality changes                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041 | Update of Detail Description of the Pharmacovigilance System (Pharmacovigilance) Changes to QPPV Update of DDPS (Pharmacovigilance)                                                                                               | 19/02/2009 | 25/03/2009 | Annex II    | The Detailed Description of the Pharmacovigilance System has been updated (Version 6.2 November 2008) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. |
| II/0038 | The MAH applied for changes in the specification, test procedures and shelf-life of the finished product . Quality changes Update of Package Leaflet                                                                              | 19/02/2009 | 25/03/2009 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0039 | he MAH applied for the addition of an alternative site of manufacture, packaging and quality control testing of the 2.5 mg/0.5 mL strength with consequential changes in the manufacturing and packaging process. Quality changes | 19/02/2009 | 04/03/2009 |             |                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0037 | The MAH applied for changes in the secondary packaging of the finished product. Update of or change(s) to the pharmaceutical documentation                                                                                        | 20/11/2008 | 22/12/2008 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IA/0040   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                 | 16/12/2008   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0036   | New presentation(s)                                                                              | 24/07/2008   | 22/08/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0035   | Update of Summary of Product Characteristics and Package Leaflet                                 | 21/02/2008   | 19/03/2008 | SmPC and PL            | Further to the results of a PK study in patients with moderate hepatic impairment, the SPC has been updated to inform physicians that no dose adjustment is necessary (section 4.2) and to include the main study findings (5.2). In addition, the warning statement (section 4.4) on Heparin Induced Thrombocytopenia (HIT) type II has been amended to reflect that rare spontaneous reports of HIT in patients treated with fondaparinux have been received, although no causal association between treatment with fondaparinux and the occurrence of HIT has been established. Finally, the statement on the prolongation of the aPTT during treatment with fondaparinux therapy (section 5.1) has been updated to inform that rare spontaneous reports of aPTT prolongation have been received. |
| N/0034    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 24/10/2007   | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0033   | Update of or change(s) to the pharmaceutical documentation                                       | 20/09/2007   | 09/10/2007 | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0032   | Update of Summary of Product Characteristics and Package Leaflet                                 | 19/07/2007   | 03/09/2007 | SmPC and PL            | Amendment of the posology (Section 4.2) for the prevention of venous thromboembolism (VTE) in patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  | with moderate renal impairment. Related changes are also proposed to Section 4.4 of the SPC and Sections 2 and 3 of the Package Leaflet. In addition, the MAH applied for minor changes to Section 4.2, 5.1 and 9 of the SPC and to Section 6 of the Package Leaflet. The Package Leaflet has been updated accordingly.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0025  | New intravenous use of the 2.5 mg strength to be administered as the first dose of fondaparinux in patients with STEMI eligible for treatment with fondaparinux (subsequent doses are administered by subcutaneous injection). Annex I_2.(e) Change or addition of a new route of administration                                                                                                                                                                                                                                                                                                                                   | 21/06/2007 | 29/08/2007 | SmPC, Labelling and PL           | Please refer to the Scientific discussion: Arixtra-H-403-X-25 and II-24.                                                                                                                                                                                                                                                  |
| II/0024 | Extension of Indication of the 2.5 mg strength to include a new indication in the treatment of Acute Coronary Syndromes as follows: Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (<120mins) invasive management (PCI) is not indicated (see sections 4.4 and 5.1). Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy The new indication is based on the results of the OASIS-5 (UA/NSTEMI) and OASIS-6 (STEMI) trials. | 21/06/2007 | 29/08/2007 | SmPC, Annex II, Labelling and PL | Please refer to the Scientific discussion: Arixtra-H-403-II- 24.                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | Extension of Indication                                                                                                                                                                                                                                                                                  |            |            |                                  |                                                                 |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------|
| IA/0031 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                       | 25/04/2007 | n/a        |                                  |                                                                 |
| R/0027  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                  | 22/02/2007 | 20/04/2007 | SmPC, Annex II, Labelling and PL |                                                                 |
| IB/0030 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                               | 07/12/2006 | n/a        | SmPC                             |                                                                 |
| IA/0028 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                         | 25/09/2006 | n/a        |                                  |                                                                 |
| IA/0026 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                 | 31/08/2006 | n/a        |                                  |                                                                 |
| IA/0023 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                       | 24/07/2006 | n/a        |                                  |                                                                 |
| IB/0022 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                                                 | 07/02/2006 | 07/02/2006 | SmPC, Labelling and PL           |                                                                 |
| II/0012 | Extension of Indication. The MAH applied for the addition of a new indication, namely \"Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery | 26/05/2005 | 07/07/2005 | SmPC and PL                      | Please refer to the Scientific discussion: Arixtra-H-403-II- 12 |

<div style=\"page-break-after: always\"></div>

|         | (see section 5.1)\" Extension of Indication                                                                                                                                                                                                               |            |            |                                  |                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------|
| IA/0020 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                     | 13/05/2005 | n/a        |                                  |                                                                      |
| II/0010 | Extension of Indication. The MAH applied for the addition of a new indication regarding `Prevention of VTE in medical patients who are at risk for thromboembolic complications due to restricted mobility during acute illness' Extension of Indication | 15/12/2004 | 25/01/2005 | SmPC and PL                      | Please refer to the Scientific discussion: Arixtra-H-403-II- 10.     |
| IB/0019 | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                                     | 17/01/2005 | n/a        |                                  |                                                                      |
| IB/0018 | IB_37_a_Change in the specification of the finished product - tightening of specification limits                                                                                                                                                         | 17/01/2005 | n/a        |                                  |                                                                      |
| IB/0017 | IB_10_Minor change in the manufacturing process of the active substance IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening                                                                                      | 17/01/2005 | n/a        |                                  |                                                                      |
| T/0014  | Transfer of Marketing Authorisation                                                                                                                                                                                                                      | 03/12/2004 | 12/01/2005 | SmPC, Annex II, Labelling and PL | Transfer of MAH from Sanofi-Synthlabo Recherche to GlaxoSmithKline. |
| IA/0015 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                        | 01/12/2004 | n/a        | SmPC, Annex II and PL            |                                                                      |

<div style=\"page-break-after: always\"></div>

|         | Extension of Indication X-3-iii_Addition of new                                                                                                                     | 29/07/2004   | 12/11/2004   | SmPC, Labelling and PL           | X/0007 strength   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------|
| N/0013  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                    | 10/09/2004   | 25/01/2005   | PL                               |                   |
| IB/0011 | IB_38_c_Change in test procedure of finished product - other changes                                                                                                | 21/07/2004   | n/a          |                                  |                   |
| IB/0009 | IB_37_a_Change in the specification of the finished product - tightening of specification limits                                                                    | 13/01/2004   | n/a          |                                  |                   |
| IB/0008 | IB_10_Minor change in the manufacturing process of the active substance IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening | 13/01/2004   | n/a          |                                  |                   |
| II/0004 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                    | 24/07/2003   | 07/11/2003   | SmPC and PL                      |                   |
| X/0005  | X-3-iii_Addition of new strength                                                                                                                                    | 24/07/2003   | 24/10/2003   | SmPC, Annex II, Labelling and PL |                   |
| I/0006  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                      | 07/08/2003   | 22/09/2003   |                                  |                   |
| II/0001 | Update of Summary of Product Characteristics                                                                                                                        | 18/12/2002   | 20/03/2003   | SmPC                             |                   |
| I/0002  | 20_Extension of shelf-life as foreseen at time of authorisation                                                                                                     | 01/12/2002   | 15/01/2003   | SmPC                             |                   |

<div style=\"page-break-after: always\"></div>

| I/0003   | 20a_Extension of shelf-life or retest period of the active substance   | 02/12/2002   | 11/12/2002   |
|----------|------------------------------------------------------------------------|--------------|--------------|